Innovation in CardioMetabolic Disease Research
Innovation in CardioMetabolic Disease Research
Search
Partnering in CardioMetabolic Diseases
Partnering in CardioMetabolic Diseases
Boehringer Ingelheim Office Hours
Boehringer Ingelheim Office Hours
About Boehringer Ingelheim Academy
About Boehringer Ingelheim Academy
Annual Declaration of Boehringer Ingelheim Corporation’s compliance with its Comprehensive Compliance Program.
Annual Declaration of Boehringer Ingelheim Corporation’s compliance with its Comprehensive Compliance Program.
Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer
Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer
National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes
National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes
First half 2019: High levels of investment in R&D and robust organic growth
First half 2019: High levels of investment in R&D and robust organic growth
Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison
Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison
New Platform: Unbridle Your Potential | Boehringer Ingelheim US
Read more on the Boehringer Ingelheim brand platform: Unbridle Your Potential, aimed at providing support and leadership for the equine industry.
Biosimilar Cyltezo® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasis
Biosimilar Cyltezo® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasis
Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists
Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists
FDA Grants Priority Review to Boehringer Ingelheim’s Biologics License Application for Idarucizumab*
FDA Grants Priority Review to Boehringer Ingelheim’s Biologics License Application for Idarucizumab*
Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate mesylate) litigation
Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate mesylate) litigation
New Long-Term Data Published in Circulation Reinforce Safety Profile of Pradaxa® (dabigatran etexilate mesylate)
New Long-Term Data Published in Circulation Reinforce Safety Profile of Pradaxa® (dabigatran etexilate mesylate)
Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer
Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer
Boehringer Ingelheim Animal Health Announces U.S. Leadership Transition
Boehringer Ingelheim Animal Health Announces U.S. Leadership Transition
Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients
Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients
Innovation in CNS Disease Research
Innovation in CNS Disease Research
Boehringer Ingelheim collaborates with Circle Pharma
Boehringer Ingelheim collaborates with Circle Pharma to develop a first-in-class cyclin RxL inhibitor that can halt the growth of cancer cells
Boehringer’s unique approach to innovation
Boehringer’s unique approach to driving patient-centric innovation
Boehringer Ingelheim Subsidiaries and Affiliate Companies
Boehringer Ingelheim Subsidiaries and Affiliate Companies
Expert insights: top online lung cancer questions answered
As part of Big Little Things, we teamed up with top patient representatives from around the world to answer the most searched questions about lung cancer.
Animal Health Partnering Interests
Learn about our Partnering Interests and how we can work together to advance innovation in animal health
Manufacturing & Supply Chain
Manufacturing & Supply Chain